Exploring new targets for diagnosing and treating Alzheimer's disease

Sialoglycoproteomic network and target discovery for Alzheimer's disease

['FUNDING_R01'] · EMORY UNIVERSITY · NIH-10906196

This study is looking at how certain proteins in the brain change in Alzheimer's disease to help find new ways to diagnose and treat the condition, which could lead to better care for patients.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorEMORY UNIVERSITY (nih funded)
Locations1 site (ATLANTA, UNITED STATES)
Trial IDNIH-10906196 on ClinicalTrials.gov

What this research studies

This research investigates the role of protein sialylation in Alzheimer's disease, aiming to uncover new molecular targets for early diagnosis and intervention. By studying how sialic acids affect protein interactions and brain function, the project seeks to identify potential biomarkers and therapeutic targets. Patients may benefit from advancements in diagnostic methods and treatment options that arise from a deeper understanding of the disease mechanisms involved. The research employs advanced biochemical techniques to analyze sialoglycoproteins and their implications in Alzheimer's pathology.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals at risk for Alzheimer's disease or those experiencing early symptoms of dementia.

Not a fit: Patients with advanced Alzheimer's disease or other forms of dementia unrelated to Alzheimer's may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved diagnostic tools and targeted therapies for Alzheimer's disease.

How similar studies have performed: Previous research has shown promise in targeting molecular pathways related to Alzheimer's disease, suggesting that this approach may yield significant insights.

Where this research is happening

ATLANTA, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease, Alzheimer's Disease Pathway

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.